Neurocrine Biosciences (NBIX) Operating Margin (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Operating Margin of 15.8% for Q2 2026, down 538.0% year-over-year from 3.61% in Q2 2025, and down 33.47% on a QoQ basis from 23.74% in Q1 2026.
Neurocrine Biosciences (NBIX) Operating Margin (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Operating Margin for 16 years, with the latest figure at 15.8% in Q2 2026.
- Operating Margin for Q2 2026 came in at 15.8%, down 538.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 23.56% (up 384.0% YoY), and the FY2025 annual result was 21.64%, down 258.0% from the prior year.
- Operating Margin retreated to 15.8% in Q2 2026, from 23.74% in the prior quarter.
- Over five years, Operating Margin peaked at 273.5% in Q2 2022 and troughed at 27.16% in Q1 2023.
- A 5-year average of 32.55% and a median of 23.19% in 2022 frame the typical range for Operating Margin.
- The widest annual swing landed in 2022, when Operating Margin jumped 25176 bps; it then sank 25724 bps in 2023.
- A 5-year view of Operating Margin shows it stood at 25.1% in 2022, then climbed by 16 bps to 29.17% in 2023, then decreased by 22 bps to 22.62% in 2024, then climbed by 16 bps to 26.18% in 2025, then plunged by 40 bps to 15.8% in 2026.
- Per Business Quant data, the three most recent Operating Margin figures were 15.8% in Q2 2026, 23.74% in Q1 2026, and 26.18% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 3.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.80% |
| Mar 31, 2026 | 23.74% |
| Dec 31, 2025 | 26.18% |
| Sep 30, 2025 | 30.07% |
| Jun 30, 2025 | 21.18% |
| Mar 31, 2025 | 4.12% |
| Dec 31, 2024 | 22.62% |
| Sep 30, 2024 | 29.55% |
| Jun 30, 2024 | 24.64% |
| Mar 31, 2024 | 19.27% |
| Dec 31, 2023 | 29.17% |
| Sep 30, 2023 | 28.31% |
| Jun 30, 2023 | 16.26% |
| Mar 31, 2023 | -27.16% |
| Dec 31, 2022 | 25.10% |
| Sep 30, 2022 | 22.63% |
| Jun 30, 2022 | 273.50% |
| Mar 31, 2022 | 1.00% |
| Dec 31, 2021 | -11.63% |
| Sep 30, 2021 | 15.03% |